Acute limb ischaemia refers to a sudden reduction in blood flow to a limb, which puts the limb at risk of tissue death. This condition is most commonly caused by either a sudden blockage of a previously partially blocked artery by a blood clot or by an embolus that travels from another part of the body. Acute limb ischaemia is considered a medical emergency, and if not promptly treated with surgery to restore blood flow, it can lead to extensive tissue damage within six hours.

The classic signs of acute limb ischaemia are often described using the 6 Ps:
– Pain that is constant and persistent
– Absence of pulses in the ankle
– Pallor, cyanosis, or mottling of the skin
– Loss of power or paralysis in the affected limb
– Paraesthesia or reduced sensation, leading to numbness
– Feeling cold in the affected limb

It is important to be able to distinguish between ischaemia caused by a blood clot and ischaemia caused by an embolus. The following highlights the main differences:
Embolus Thrombus
– Onset is sudden, occurring within seconds to minutes – Onset is gradual, taking hours to days
– Ischaemia is usually severe due to the lack of collateral circulation – Ischaemia is less severe due to the presence of collateral circulation
– There is typically no history of claudication, and pulses may still be present in the other leg – There is often a history of claudication, and pulses may also be absent in the other leg
– Skin changes, such as marbling, may be visible in the feet. This can appear as a fine reticular blanching or mottling in the early stages, progressing to coarse, fixed mottling
– Skin changes are usually absent in cases of thrombus-induced ischaemia.

Patients with active cancer and a confirmed deep-vein thrombosis (DVT) should be considered for treatment with a direct oral anticoagulant (DOAC) such as apixaban. If a DOAC is not suitable for the patient, alternative options should be offered. One option is the use of low-molecular-weight heparin (LMWH) alone. Another option is the combination of LMWH and a vitamin K antagonist (VKA) like warfarin, which should be given for at least 5 days or until the international normalized ratio (INR) reaches at least 2.0 on 2 consecutive readings. After achieving the desired INR, the patient can continue with a VKA alone. It is important to note that anticoagulation treatment should be offered for a period of 3-6 months. to the NICE guidance on the diagnosis and management of venous thromboembolism.

The current guidelines from NICE recommend that the first-line treatment for confirmed deep-vein thrombosis (DVT) or pulmonary embolism (PE) should be either apixaban or rivaroxaban, which are direct oral anticoagulants.

If neither of these options is suitable, the following alternatives should be considered:

1. LMWH (low molecular weight heparin) should be administered for at least 5 days, followed by dabigatran or edoxaban.

2. LMWH should be combined with a vitamin K antagonist (VKA), such as warfarin, for at least 5 days or until the international normalized ratio (INR) reaches at least 2.0 on 2 consecutive readings. Afterward, the VKA can be continued alone.

The NICE guidelines for suspected deep vein thrombosis (DVT) suggest considering the possibility of DVT if typical symptoms and signs are present, particularly if the person has risk factors like previous venous thromboembolism and immobility.

Typical signs and symptoms of DVT include unilateral localized pain (often throbbing) that occurs during walking or bearing weight, as well as calf swelling (or, less commonly, swelling of the entire leg). Other signs to look out for are tenderness, skin changes such as edema, redness, and warmth, and vein distension.

To rule out other potential causes for the symptoms and signs, it is important to conduct a physical examination and review the person’s general medical history.

When assessing leg and thigh swelling, it is recommended to measure the circumference of the leg 10 cm below the tibial tuberosity and compare it with the unaffected leg. A difference of more than 3 cm between the two legs increases the likelihood of DVT.

Additionally, it is important to check for edema and dilated collateral superficial veins on the affected side.

To assess the likelihood of DVT and guide further management, the two-level DVT Wells score can be used.

For more information, you can refer to the NICE Clinical Knowledge Summary on deep vein thrombosis.

When managing a first episode of acute venous thromboembolism (VTE), it is recommended to start warfarin in combination with a parenteral anticoagulant, such as unfractionated heparin, low-molecular-weight heparin, or fondaparinux. The parental anticoagulant should be continued for a minimum of 5 days and ideally until the international normalized ratio (INR) is above 2 for at least 24 hours.

To prevent the extension of the blood clot and recurrence in calf deep vein thrombosis (DVT), at least 6 weeks of anticoagulant therapy is necessary. For proximal DVT, a minimum of 3 months of anticoagulant therapy is required.

For first episodes of VTE, the ideal target INR is 2.5. However, in cases where patients experience recurrent VTE while being anticoagulated within the therapeutic range, the target INR should be increased to 3.5.

The current guidelines from NICE recommend that the first-line treatment for confirmed deep-vein thrombosis (DVT) or pulmonary embolus (PE) should be either apixaban or rivaroxaban, which are direct oral anticoagulants.

If neither of these options is suitable, the following alternatives should be considered:

1. LMWH (low molecular weight heparin) should be administered for at least 5 days, followed by dabigatran or edoxaban.

2. LMWH should be combined with a vitamin K antagonist (VKA), such as warfarin, for at least 5 days or until the international normalized ratio (INR) reaches at least 2.0 on 2 consecutive readings. Afterward, the VKA can be continued alone.

Acute limb ischaemia refers to a sudden reduction in blood flow to a limb, which puts the limb’s viability at risk. This condition is most commonly caused by either a sudden blockage of a previously partially blocked artery due to a blood clot or by an embolus that travels from a distant site. It is considered a surgical emergency, as without prompt surgical intervention, complete acute ischaemia can lead to extensive tissue death within six hours.

The leading cause of acute limb ischaemia is the sudden blockage of a narrowed arterial segment due to a blood clot, accounting for 60% of cases. The second most common cause is an embolism, which makes up 30% of cases. Emboli can originate from various sources, such as a blood clot in the left atrium of patients with atrial fibrillation (which accounts for 80% of peripheral emboli), a clot formed on the heart’s wall following a heart attack, or from prosthetic heart valves. It is crucial to differentiate between these two conditions, as their treatment and prognosis differ.

To properly investigate acute limb ischaemia, several important tests should be arranged. These include a hand-held Doppler ultrasound scan, which can help determine if there is any remaining arterial flow. Blood tests, such as a full blood count, erythrocyte sedimentation rate, blood glucose level, and thrombophilia screen, are also necessary. If there is uncertainty regarding the diagnosis, urgent arteriography should be performed.

In cases where an embolus is suspected as the cause, additional investigations are needed to identify its source. These may include an electrocardiogram to detect atrial fibrillation, an echocardiogram to assess the heart’s function, an ultrasound of the aorta, and ultrasounds of the popliteal and femoral arteries.

By rewriting the explanation and using paragraph spacing, the information is presented in a clearer and more organized manner.

Acute limb ischaemia refers to a sudden decrease in blood flow to a limb, which puts the limb at risk of tissue death. This condition is most commonly caused by either a sudden blockage of a partially blocked artery or an embolus that travels from another part of the body. It is considered a surgical emergency, as without prompt surgical intervention, the limb may suffer extensive tissue damage within six hours.

The typical signs of acute limb ischaemia are often described using the 6 Ps: constant and persistent pain, absence of pulses in the ankle, paleness or discoloration of the limb, loss of power or paralysis, reduced sensation or numbness, and a sensation of coldness. The leading cause of acute limb ischaemia is a sudden blockage of a previously narrowed artery (60% of cases). The second most common cause is an embolism, such as from a blood clot in the heart or following a heart attack. It is important to differentiate between these two causes, as the treatment and prognosis differ.

Other potential causes of acute limb ischaemia include trauma, Raynaud’s syndrome, iatrogenic injury (caused by medical procedures), popliteal aneurysm, aortic dissection, and compartment syndrome. If acute limb ischaemia is suspected, it is crucial to seek immediate assessment by a vascular surgeon.

The management of acute limb ischaemia in a hospital setting depends on factors such as the type and location of the blockage, duration of ischaemia, presence of other medical conditions, type of blood vessel affected, and the viability of the limb. Treatment options may include percutaneous catheter-directed thrombolytic therapy, surgical embolectomy, or endovascular revascularisation if the limb can still be saved. The choice between surgical and endovascular techniques will depend on various factors, including the urgency of revascularisation and the severity of sensory and motor deficits.

In cases where the limb is beyond salvage, amputation may be necessary. This is because attempting to revascularise a limb with irreversible ischaemia and extensive muscle death can lead to a condition called reperfusion syndrome, which can cause inflammation and damage to multiple organs, potentially resulting in death.

The NICE guidelines for suspected deep vein thrombosis (DVT) suggest considering the possibility of DVT if typical symptoms and signs are present, particularly if the person has risk factors like previous venous thromboembolism and immobility.

Typical signs and symptoms of DVT include unilateral localized pain (often throbbing) that occurs during walking or bearing weight, as well as calf swelling (or, less commonly, swelling of the entire leg). Other signs to look out for are tenderness, skin changes such as edema, redness, and warmth, and vein distension.

To rule out other potential causes for the symptoms and signs, it is important to conduct a physical examination and review the person’s general medical history.

When assessing leg and thigh swelling, it is recommended to measure the circumference of the leg 10 cm below the tibial tuberosity and compare it with the unaffected leg. A difference of more than 3 cm between the two legs increases the likelihood of DVT.

Additionally, it is important to check for edema and dilated collateral superficial veins on the affected side.

To assess the likelihood of DVT and guide further management, the two-level DVT Wells score can be used.

For more information, you can refer to the NICE Clinical Knowledge Summary on deep vein thrombosis.

An abdominal aortic aneurysm (AAA) is a condition where the abdominal aorta becomes enlarged, either in a specific area or throughout its length, reaching 1.5 times its normal size. Most AAAs are found between the diaphragm and the point where the aorta splits into two branches. They can be classified into three types based on their location: suprarenal, pararenal, and infrarenal. Suprarenal AAAs involve the origin of one or more visceral arteries, pararenal AAAs involve the origins of the renal arteries, and infrarenal AAAs start below the renal arteries. The majority of AAAs (approximately 85%) are infrarenal. In individuals over 50 years old, a normal infrarenal aortic diameter is 1.7 cm in men and 1.5 cm in women. An infrarenal aorta with a diameter greater than 3 cm is considered to be an aneurysm. While most AAAs do not cause symptoms, an expanding aneurysm can sometimes lead to abdominal pain or pulsatile sensations. Symptomatic AAAs have a high risk of rupture. In the UK, elective surgery for AAAs is typically recommended if the aneurysm is larger than 5.5 cm in diameter or if it is larger than 4.5 cm in diameter and has increased in size by more than 0.5 cm in the past six months.